Charles E. Cooley

Array ( [id] => 18902738 [patent_doc_number] => 20240018223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => REP PROTEIN AS PROTEIN ANTIGEN FOR USE IN DIAGNOSTIC ASSAYS [patent_app_type] => utility [patent_app_number] => 18/335440 [patent_app_country] => US [patent_app_date] => 2023-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18335440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18831946 [patent_doc_number] => 20230400473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => METHODS AND COMPOSITIONS FOR THE TREATMENT OF CROHN'S DISEASE [patent_app_type] => utility [patent_app_number] => 18/207707 [patent_app_country] => US [patent_app_date] => 2023-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7227 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18207707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895233 [patent_doc_number] => 20240010718 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => METHOD OF TREATING INFLAMMATORY BOWEL DISEASE WITH A COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF ALPHA [patent_app_type] => utility [patent_app_number] => 18/327577 [patent_app_country] => US [patent_app_date] => 2023-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18425 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18327577 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097767 [patent_doc_number] => 20240116995 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => MUTANT FGF-21 PEPTIDE PEGYLATED CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/326510 [patent_app_country] => US [patent_app_date] => 2023-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30627 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 117 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18326510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709203 [patent_doc_number] => 20230331815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTION [patent_app_type] => utility [patent_app_number] => 18/321610 [patent_app_country] => US [patent_app_date] => 2023-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18321610 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18879146 [patent_doc_number] => 20240002515 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => METHODS AND ANTIBODIES FOR MODULATION OF IMMUNORESPONSE [patent_app_type] => utility [patent_app_number] => 18/319817 [patent_app_country] => US [patent_app_date] => 2023-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18319817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709220 [patent_doc_number] => 20230331832 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND TO MATRILIN 3 AND THEIR USE [patent_app_type] => utility [patent_app_number] => 18/317869 [patent_app_country] => US [patent_app_date] => 2023-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34116 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 204 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18317869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19969679 [patent_doc_number] => 12338271 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-06-24 [patent_title] => Fusion protein including GIP and FGF21 and compositions thereof [patent_app_type] => utility [patent_app_number] => 18/313282 [patent_app_country] => US [patent_app_date] => 2023-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 0 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18313282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265323 [patent_doc_number] => 20240209022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => NOVEL PEPTIDE HAVING ANTI-INFLAMMATORY AND TISSUE REGENERATIVE ACTIONS [patent_app_type] => utility [patent_app_number] => 18/312110 [patent_app_country] => US [patent_app_date] => 2023-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24440 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312110 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556476 [patent_doc_number] => 20240368268 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => METHOD OF MODULATING THE ACTIVITY OF ADRENOMEDULLIN IN A SUBJECT IN NEED OF THERAPEUTIC INTERVENTION FOR ORGAN DYSFUNCTION OR ORGAN FAILURE ASSOCIATED WITH ADRENOMEDULLIN (ADM) ACTIVITY BY ADMINISTERING AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM FRAGMENT TO THE SUBJECT [patent_app_type] => utility [patent_app_number] => 18/142070 [patent_app_country] => US [patent_app_date] => 2023-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29268 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18142070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612358 [patent_doc_number] => 20230279090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => NON-COVALENT PROTEIN-HYALURONAN CONJUGATES FOR LONG-ACTING OCULAR DELIVERY [patent_app_type] => utility [patent_app_number] => 18/301187 [patent_app_country] => US [patent_app_date] => 2023-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41484 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18301187 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861942 [patent_doc_number] => 20230416378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => ANTI-NRP1A ANTIBODIES AND THEIR USES FOR TREATING EYE OR OCULAR DISEASES [patent_app_type] => utility [patent_app_number] => 18/297154 [patent_app_country] => US [patent_app_date] => 2023-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24706 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18297154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18923029 [patent_doc_number] => 20240026033 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/194276 [patent_app_country] => US [patent_app_date] => 2023-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39202 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18194276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20492640 [patent_doc_number] => 12534503 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => Mutant fibroblast growth factor 21 (FGF21) polypeptides [patent_app_type] => utility [patent_app_number] => 18/176172 [patent_app_country] => US [patent_app_date] => 2023-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 30 [patent_no_of_words] => 17854 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18176172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097802 [patent_doc_number] => 20240117030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => MULTISPECIFIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/175796 [patent_app_country] => US [patent_app_date] => 2023-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 152384 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18175796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18861918 [patent_doc_number] => 20230416353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => TREATMENT OF OPHTHALMOLOGIC DISEASES [patent_app_type] => utility [patent_app_number] => 18/166996 [patent_app_country] => US [patent_app_date] => 2023-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30010 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18166996 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18510053 [patent_doc_number] => 20230226151 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-20 [patent_title] => Methods for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and Diseases [patent_app_type] => utility [patent_app_number] => 18/158713 [patent_app_country] => US [patent_app_date] => 2023-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33841 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 121 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18158713 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20143985 [patent_doc_number] => 12378312 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-05 [patent_title] => Polynucleotides encoding human beta klotho antibodies or binding fragments thereof and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/153643 [patent_app_country] => US [patent_app_date] => 2023-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 65782 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18153643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612397 [patent_doc_number] => 20230279129 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => METHOD OF TREATING OR PREVENTING ISCHEMIA-REPERFUSION INJURY [patent_app_type] => utility [patent_app_number] => 18/152439 [patent_app_country] => US [patent_app_date] => 2023-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28357 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18152439 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18498627 [patent_doc_number] => 20230221339 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => ADRENOMEDULLIN (ADM) FOR DIAGNOSIS AND/OR PREDICTION OF DEMENTIA AND ANTI-ANDRENOMEDULLIN BINDER FOR USE IN THERAPY OR PREVENTION OF DEMENTIA [patent_app_type] => utility [patent_app_number] => 18/148633 [patent_app_country] => US [patent_app_date] => 2022-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19314 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18148633 [rel_patent_id] =>[rel_patent_doc_number] =>)